vatalanib has been researched along with sgi 1776 in 1 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (sgi 1776) | Trials (sgi 1776) | Recent Studies (post-2010) (sgi 1776) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 59 | 0 | 56 |
| Protein | Taxonomy | vatalanib (IC50) | sgi 1776 (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase Yes | Homo sapiens (human) | 1.455 | |
| Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | 0.0158 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.007 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.362 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.0382 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.069 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.8727 | |
| Serine/threonine-protein kinase pim-3 | Homo sapiens (human) | 0.0659 | |
| Serine/threonine-protein kinase haspin | Homo sapiens (human) | 0.034 | |
| Serine/threonine-protein kinase pim-2 | Homo sapiens (human) | 0.4053 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
1 other study(ies) available for vatalanib and sgi 1776
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |